Epizyme closed another pharma deal with Eisai to develop drugs against lymphomas and other cancers. Epizyme will get $6 million upfront and can earn up to another $200 million in milestones. The deal gives Eisai access to Epizymes EZH2 epigenetic enzyme targets.
Eisai continues its investment in cancer targets and technologies. In addition to the EZH2 targe for therapies, Eisai and epizyme plan to produce a companion diagnostic to select patients who will be most responsive to the drugs that are deeveloped. This will be similar to the approach taken with Roche's Herceptin and Plexxikon/Roche's PLX4032. See Xconomy Boston.
Posted by Bruce Lehr March 13th 2011.
Comments